Structure Therapeutics Inc.的股价在其实验性减肥药aleniglipron的数据公布后上涨。数据显示，患者在服用44周后，体重减轻了约15%。BMO资本市场分析师Evan Seigerman指出，该药物的疗效“看起来极具竞争力”，甚至可能优于诺和诺德和礼来的同类口服药。Structure计划在2026年下半年启动后期研究，采用“低量且缓慢”的剂量滴定法以预防胃肠道副作用。
Structure Therapeutics Inc.的股价在其实验性减肥药aleniglipron的数据公布后上涨。数据显示，患者在服用44周后，体重减轻了约15%。BMO资本市场分析师Evan Seigerman指出，该药物的疗效“看起来极具竞争力”，甚至可能优于诺和诺德和礼来的同类口服药。Structure计划在2026年下半年启动后期研究，采用“低量且缓慢”的剂量滴定法以预防胃肠道副作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.